Stockscreener 앱 받기
8.80
8.62%
-0.83
시장 영업 전:
8.80
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
What are the latest earnings results for Phathom Pharmaceuticals Inc.High-octane financial growth - jammulinksnews.com
Phathom Pharmaceuticals to Host Conference Call for Q2 2025 Financial Results on August 7, 2025 - Quiver Quantitative
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 - The Manila Times
Phathom Pharmaceuticals to Report Second Quarter 2025 - GlobeNewswire
What is Phathom Pharmaceuticals Inc. company’s growth strategyInvest with confidence backed by data - jammulinksnews.com
Is it the right time to buy Phathom Pharmaceuticals Inc. stockAI Powered Review For 2025 - jammulinksnews.com
How does Phathom Pharmaceuticals Inc. generate profit in a changing economyTop Growth Planner That Work - jammulinksnews.com
What are the technical indicators suggesting about Phathom Pharmaceuticals Inc.Rapid market gains - jammulinksnews.com
Is Phathom Pharmaceuticals Inc. a growth stock or a value stockDiscover hidden gems in the stock market - jammulinksnews.com
What makes Phathom Pharmaceuticals Inc. stock price move sharplyFree Real-Time Market Predictions - metal.it
How many analysts rate Phathom Pharmaceuticals Inc. as a “Buy”Discover undervalued opportunities early - jammulinksnews.com
What is the risk reward ratio of investing in Phathom Pharmaceuticals Inc. stockMaximize profits with strategic stock selection - jammulinksnews.com
What analysts say about Phathom Pharmaceuticals Inc. stockFree Capital Allocation Plans - jammulinksnews.com
Is Phathom Pharmaceuticals Inc. a good long term investmentFree Daily Trading Room Entry - jammulinksnews.com
Phathom Pharmaceuticals Inc. Stock Analysis and ForecastConsistent triple returns - jammulinksnews.com
What drives Phathom Pharmaceuticals Inc. stock priceBreakout portfolio performance - jammulinksnews.com
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge - simplywall.st
Phathom Pharmaceuticals' Principal Accounting Officer Robert Charles Sells 1692 Shares at $8.36. - AInvest
When Will Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Turn A Profit? - 富途牛牛
Analysts Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Target Price at $17.50 - Defense World
Why Phathom Pharmaceuticals Inc. stock attracts strong analyst attentionShort Squeeze Radar - Newser
How Phathom Pharmaceuticals Inc. stock performs during market volatilityGrowth Stock Monitor - Newser
How To Trade (PHAT) - news.stocktradersdaily.com
Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Profit Outlook - simplywall.st
Phathom Pharmaceuticals: A Path to Profitability and a Billion-Dollar Horizon with Voquezna? - AInvest
Phathom Pharmaceuticals shares rise 1.47% premarket after Cidara Therapeutics closes $402.5 million stock offering. - AInvest
Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism - Seeking Alpha
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - GlobeNewswire
FDA Approval for VOQUENZA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC - Quantisnow
Phathom says FDA confirmed Voqueza exclusivity through May 2032 - MSN
Phathom Pharmaceuticals Announces FDA Correction to Orange - GlobeNewswire
1.32%
1.06%
자본화:
|
볼륨(24시간):